Corrigendum to ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa [Cytotherapy 25 (2023) 782-788/1562].

The authors regret that the following funding information was missed: Contributions by JT to this work were supported by National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grant #R01AR063070. The authors would like to apologize for any inconvenience caused. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosaCytotherapyVol. 25Issue 7PreviewRecessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating and life-threatening inherited skin fragility disorder caused by biallelic mutations in the COL7A1 gene [1]. Lack of functional type VII collagen causes an extremely impaired mechanical cutaneous stability, which manifests with recurrently blistering and non-healing chronic wounds [2,3]. Persistent skin inflammation significantly contributes to symptom severity and disease complications [4,5]. Dermal mesenchymal stromal cells (MSCs) expressing the ABC transporter ABCB5 [6] are capable, upon systemic administration, of efficiently migrating and homing to skin wounds [7] and dampening interleukin 1 (IL-1)–driven skin inflammation [8]. Full-Text PDF Open Access